Marker Therapeutics (GX1) Price & Analysis

1 Followers

GX1 Stock Chart & Stats

€1.22

-€0.10(-3.52%)

At close: Jan 08 4:00 PM EST

€1.22

-€0.10(-3.52%)

Day’s Range― - ―

52-Week Range€0.58 - €1.72

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€18.16M

Enterprise Value€9.47

Total Cash (Recent Filing)€14.92M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Aug 19, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.67

Shares Outstanding16,673,126

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.36

Price to Sales (P/S)0.00

P/FCF Ratio-1.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€7.90

Price Target Upside547.93% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.83

Revenue Forecast (FY)€2.35M

Bulls Say, Bears Say

Bulls Say

Low Leverage / No Reported DebtA consistent zero debt position materially reduces interest burden and financial risk, giving management greater flexibility to time equity raises or partnerships. For a cash-burning clinical biotech, low leverage lessens refinancing pressure and preserves optionality for multi‑year R&D programs.

MultiTAA T-cell Therapy PlatformA platform that targets multiple tumor antigens can be a durable competitive advantage if validated: it broadens addressable indications, reduces single‑antigen escape risk, and supports modular pipeline expansion and partnerships. Platform strengths persist beyond short‑term cycles if clinical data progress.

Authorized Share Increase Expands Financing OptionalityA materially higher authorized share ceiling provides structural flexibility to raise equity or complete strategic transactions without repeated charter amendments. For a clinical-stage firm with ongoing cash burn, this long-term governance tool improves capital‑raising agility and supports sustained R&D investment.

Bears Say

Persistent Negative Operating Cash FlowChronic negative operating cash flow indicates the business cannot self‑fund its development pipeline, forcing recurring external financing. That reliance increases dilution risk and constrains strategic choices, making long‑term execution dependent on capital markets or partner deals rather than internal cash generation.

Declining Revenue And Negative Gross ProfitFalling revenues combined with negative gross profit show the core activities are not yet economically sustainable. Persistent losses and unstable top‑line trends make margin recovery uncertain absent successful clinical milestones or licensing, raising the bar for reaching durable profitability.

Clinical‑stage R&D Focus With No Commercial RevenueBeing clinical‑stage means revenue is reliant on trial outcomes, partnerships, or licensing rather than product sales. Long, costly development timelines and high trial failure rates create structural execution and financing risk until regulatory approval and commercialization capability are demonstrated.

Marker Therapeutics News

Marker Therapeutics: Buy Rating Reaffirmed with Unchanged $8 Price Target on Optimism for MT-601 Data and Pivotal Pathway

Analyst John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics and keeping the price target...

24d ago

MRKR

Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Marker Therapeutics, retaining the price target of...

2M ago

MRKR

MRKR Upcoming Earnings Report: What to Expect?

Marker Therapeutics (MRKR) is scheduled to report 1st quarter earnings on 05/20/2026. Regarding Q1 estimates, Wall Street analysts...

2M ago

MRKR

Marker Therapeutics Shareholders Approve Governance and Capital Changes

Marker Therapeutics ( ($MRKR) ) has shared an announcement. At its May 1, 2026 annual meeting, Marker Therapeutics’...

3M ago

MRKR

Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Marker Therapeutics and keeping the price target...

4M ago

MRKR

Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones

The latest update is out from Marker Therapeutics ( ($MRKR) ). Marker Therapeutics reported 2025 results highlighting clinical...

4M ago

MRKR

Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward

Marker Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst John Newman from...

4M ago

MRKR

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

Reports FY25 revenue $3.5M, consensus $3.1M. “In 2025, we continued to advance MT-601, our lead Multi-Antigen Recognizing (MAR)-T...

4M ago

MRKR

Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet

Marker Therapeutics (MRKR) is scheduled to report 4th quarter earnings on 03/12/2026. Regarding Q4 estimates, Wall Street analysts...

5M ago

MRKR

Marker Therapeutics Sets Date for 2026 Annual Meeting

The latest announcement is out from Marker Therapeutics ( ($MRKR) ). On February 9, 2026, Marker Therapeutics, Inc....

5M ago

MRKR

Marker announces Baylor’s TACTOPS study featured on Good Morning America

Marker Therapeutics (MRKR) announced that Baylor College of Medicine’s TACTOPS clinical study in pancreatic cancer was featured on...

6M ago

MRKR

Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target

Marker Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from...

7M ago

MRKR

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells,...

7M ago

MRKR

Marker Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $10 price...

8M ago

MRKR

GX1 FAQ

What was Marker Therapeutics’s price range in the past 12 months?

Marker Therapeutics lowest stock price was €0.57 and its highest was €1.72 in the past 12 months.

What is Marker Therapeutics’s market cap?

Marker Therapeutics’s market cap is €18.16M.

When is Marker Therapeutics’s upcoming earnings report date?

Marker Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 26 days.

How were Marker Therapeutics’s earnings last quarter?

Marker Therapeutics released its earnings results on May 20, 2026. The company reported -€0.141 earnings per share for the quarter, the consensus estimate of -€0.141 by €0.

Is Marker Therapeutics overvalued?

According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Marker Therapeutics pay dividends?

Marker Therapeutics does not currently pay dividends.

What is Marker Therapeutics’s EPS estimate?

Marker Therapeutics’s EPS estimate is -0.19.

How many shares outstanding does Marker Therapeutics have?

Marker Therapeutics has 16,673,126 shares outstanding.

What happened to Marker Therapeutics’s price movement after its last earnings report?

Marker Therapeutics reported an EPS of -€0.141 in its last earnings report, expectations of -€0.141. Following the earnings report the stock price went up 0.962%.

Which hedge fund is a major shareholder of Marker Therapeutics?

Currently, no hedge funds are holding shares in DE:GX1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Marker Therapeutics (GX1) Earnings & Revenues

Historic Earnings Reports

GX1 Stock 12 Month Forecast

Average Price Target

€7.90

▲(547.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","9":"€9","-1":"-€1","1.5":"€1.5","6.5":"€6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.7830165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.90471485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.0264132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.14,1.7279243461538463,2.3158486923076924,2.903773038461539,3.491697384615385,4.079621730769231,4.667546076923077,5.255470423076924,5.84339476923077,6.431319115384616,7.019243461538462,7.607167807692308,8.195092153846156,{"y":8.7830165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.14,1.6603626807692309,2.1807253615384616,2.701088042307693,3.2214507230769236,3.7418134038461544,4.262176084615385,4.782538765384616,5.302901446153847,5.823264126923077,6.343626807692308,6.863989488461539,7.3843521692307705,{"y":7.90471485,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.14,1.5928010153846153,2.045602030769231,2.4984030461538462,2.9512040615384616,3.4040050769230774,3.856806092307693,4.309607107692308,4.7624081230769235,5.215209138461539,5.668010153846154,6.12081116923077,6.573612184615385,{"y":7.0264132,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.705,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.975,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >